Allergy Therapeutics, a UK-based fully integrated pharmaceutical company specialising in allergy vaccines, has appointed of Dr Daphne Tsitoura as Head of Clinical Science. She will lead the clinical development team in Worthing, West Sussex and Munich, Germany.
Tsitoura joins Allergy Therapeutics from GSK, where she has spent the last eight years as Principal Physician in the Respiratory Therapeutic Area at GSKs’ Stevenage Research Centre UK and has maintained a clinical link with allergy as an associate allergist at University College Hospital, London.
Previously she has held roles of Principal Immunologist at the Institute of Biomedical Research Academy of Athens, Consultant Physician/Chief of the Allergy Unit at the Henry Dunant Hospital, Athens, senior fellow in immunology and allergy at Stanford University School of Medicine, Palo Alto US, and associate professor in Respiratory Medicine College of Physicians and Surgeons, Columbia University New York, US.
Tim Higenbottam, R&D Director at Allergy Therapeutics, said: 'With an impressive career in medicine development and allergy, Daphne brings to Allergy Therapeutics a passion and drive to enhance the ease of use of allergy vaccines. She has a great depth of understanding of the therapeutic methods of modulation of the innate immune system to optimise allergy therapies. Her expertise will lend enormous support and strengthen our team of pharmaceutical experts and drive the research to gain approval of our Pollinex Quattro ultra-short course allergy vaccines in Europe and US.'
